Abstract 838P
Background
In the survival prognosis of patients with multiple myeloma, there are staging models based on Cox survival models. Current staging models do not include patients with missing data, although there are multiple investigations where the problem of missing information is very common. This situation causes results that do not represent the reality of the populations, generating biases in the true results of the research and excluding patients both in training and in the application of the model to new patients.
Methods
To solve this problem, a survival model based on Bayesian statistics was built that not only allowed us to impute the missing data of patients with multiple Myeloma using statistical methods but also allowed us to predict new patients with missing data. This model was built and tuned using data from multiple myeloma patients from a public database from a study conducted in Arkansas.
Results
The results of the Bayesian model allowed us to estimate the survival of patients with missing information. Additionally, when compared with the classic Cox models in patients with complete data, the performance metrics did not deteriorate (concordance index of 72% and 71% respectively) in patients with complete data. In addition, it allows for estimating survival and staging the risk of patients with multiple myeloma with missing data, maintaining the concordance rate at 71%.
Conclusions
A model that performs as well as Cox models in patients with complete data and maintains this performance in patients with missing data is achieved. It also allows the prediction of new patients who are diagnosed with multiple myeloma without the restriction that their complete clinical or genetic data is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
835P - Genetic, epigenetic, and clinical significance of Wilms’ tumor 1 (WT1) gene in acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract
836P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract
837P - Expression analysis, clinical significance and potential function of ALOX5AP in acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract
839P - Preliminary results from a phase II study of amulirafusp alfa (IMM0306) in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
Presenter: jianliang yang
Session: Poster session 09
840P - Orelabrutinib-based regimens in chronic lymphocytic leukemia with comorbidities: A real-world study
Presenter: Xun Lai
Session: Poster session 09
841P - Transforming the landscape of pediatric AML treatment: A cutting-edge SCT prognostic model
Presenter: Hua Yang
Session: Poster session 09
Resources:
Abstract
842P - Exploring the association of side-effects with depression in patients with chronic lymphocytic leukemia who have received treatment: An analysis of the lymphoma coalition’s 2022 global patient survey
Presenter: Natacha Bolanos Fernandez
Session: Poster session 09
843P - Challenges and insights in treating Langerhans cell histiocytosis: Persistent mutations and novel therapeutic approaches
Presenter: Marzieh NASHVI
Session: Poster session 09
844TiP - Orelabrutinib combined with rituximab for the treatment of elderly patients with newly diagnosed non-GCB diffuse large B-cell lymphoma (DLBCL) under the guidance of genetic subtype: A prospective, multicenter, single-arm, response-adaptive clinical study (Origin)
Presenter: Wanzhuo Xie
Session: Poster session 09
845TiP - CNS lymphoma imaging and molecular biomarkers study: CLIMB
Presenter: Panagiotis Ntellas
Session: Poster session 09